KCM
REGN icon

Kathmere Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Kathmere Capital Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-286
Closed -$138K – 338
2020
Q4 		$138K Hold
286
– – 0.03% 164
2020
Q3 		$160K Buy
+286
New +$173K 0.04% 127
2020
Q1 		– Sell
-652
Closed -$245K – 114
2019
Q4 		$245K Buy
+652
New +$219K 0.09% 90

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Kathmere Capital Management's REGN Position: Q1 2021 in Review

Kathmere Capital Management sold out of Regeneron Pharmaceuticals (REGN) in Q1 2021, closing a stake of 286 shares — an estimated $138K sold.

Kathmere Capital Management first reported a position in REGN in Q4 2019 and held it in 3 quarters. The position peaked at $245K in Q4 2019. 924 funds tracked by Wall St. Rank hold REGN as of Q1 2021.

  • Kathmere Capital Management reported no remaining Regeneron Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Kathmere Capital Management sold 286 Regeneron Pharmaceuticals shares in Q1 2021, an estimated $138K.
  • Kathmere Capital Management first reported a position in Regeneron Pharmaceuticals in Q4 2019 and held it in 3 quarters.
  • Kathmere Capital Management's Regeneron Pharmaceuticals position peaked at $245K in Q4 2019.
  • 924 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2021.

Based on Kathmere Capital Management's 13F filing for Q1 2021, filed 7 May 2021.